PROK

SEC source: 0001104659-23-108414 · tm2328094-1_4seq1.xml · nonDerivative · entry 1

Palihapitiya Chamath · CIK 0001715450 · 10% owner

SC Master Holdings, LLC · CIK 0001851024 · 10% owner

SC PIPE Holdings LLC · CIK 0001938696 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 9,447,379

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.6812 to $4.8148. The reporting person undertakes to provide ProKidney Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.direct: Represents shares held by SC PIPE Holdings LLC ("PIPE Holdings"). PIPE Holdings is controlled by Mr. Palihapitiya and SC Master Holdings, LLC ("Master Holdings") is the sole member of PIPE Holdings. Mr. Palihapitiya and Master Holdings may be deemed to beneficially own shares held directly by PIPE Holdings by virtue of their indirect or direct interests in PIPE Holdings or their control over PIPE Holdings, as the case may be.

F2 · ownership.nature: Represents shares held by SC PIPE Holdings LLC ("PIPE Holdings"). PIPE Holdings is controlled by Mr. Palihapitiya and SC Master Holdings, LLC ("Master Holdings") is the sole member of PIPE Holdings. Mr. Palihapitiya and Master Holdings may be deemed to beneficially own shares held directly by PIPE Holdings by virtue of their indirect or direct interests in PIPE Holdings or their control over PIPE Holdings, as the case may be.

SEC source: 0001104659-23-102847 · tm2326457-1_4seq1.xml · nonDerivative · entry 1

Palihapitiya Chamath · CIK 0001715450 · 10% owner

SC Master Holdings, LLC · CIK 0001851024 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 2,073,000

F1 · ownership.direct: Represents shares held by SC Master Holdings, LLC ("Master Holdings"). Master Holdings is controlled by Mr. Palihapitiya. Mr. Palihapitiya may be deemed to beneficially own shares held by Master Holdings by virtue of his indirect interests in Master Holdings or his control over Master Holdings, as the case may be.

F1 · ownership.nature: Represents shares held by SC Master Holdings, LLC ("Master Holdings"). Master Holdings is controlled by Mr. Palihapitiya. Mr. Palihapitiya may be deemed to beneficially own shares held by Master Holdings by virtue of his indirect interests in Master Holdings or his control over Master Holdings, as the case may be.

SEC source: 0000950170-23-045159 · ownership.xml · derivative · entry 3

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 539,356

Underlying: Class A Ordinary Shares · 137,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for Class A Ordinary Shares on a one-for-one basis. On August 25, 2023, the reporting person provided ProKidney Corp. (the "Issuer") with notice of exchange, which exchange will be settled 60 days following the closing of the exchange period under the terms of the Exchange Agreement.

F3 · derivative.exercise_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

F3 · derivative.expiration_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

SEC source: 0000950170-23-045159 · ownership.xml · derivative · entry 2

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 539,356

Underlying: Class A Ordinary Shares · 137,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for Class A Ordinary Shares on a one-for-one basis. On August 25, 2023, the reporting person provided ProKidney Corp. (the "Issuer") with notice of exchange, which exchange will be settled 60 days following the closing of the exchange period under the terms of the Exchange Agreement.

F2 · derivative.exercise_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

F2 · derivative.expiration_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

SEC source: 0000950170-23-045159 · ownership.xml · nonDerivative · entry 1

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-044316 · doc4.xml · derivative · entry 1

Culleton Bruce · CIK 0001983742 · EVP, Clinical Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 485,000

Underlying: Class A Ordinary Shares · 485,000 shares

Expires 2033-08-01

F1 · derivative.exercise_date: The option vests 25% on 1st anniversary of August 1, 2023 and the remaining 75% vests in substantially equal monthly installments for 36 months thereafter.

SEC source: 0001209191-23-042197 · doc4.xml · derivative · entry 2

Fox Jennifer A. · CIK 0001841557 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,515

Underlying: Class A Ordinary Shares · 42,515 shares

Expires 2033-07-12

F2 · derivative.exercise_date: The option shall vest and become exercisable in two equal annual installments on July 11, 2024 and July 11, 2025 subject to Ms. Fox's continued service with the Company through the applicable vesting date.

SEC source: 0001209191-23-042197 · doc4.xml · derivative · entry 1

Fox Jennifer A. · CIK 0001841557 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,632

Underlying: Class A Ordinary Shares · 46,632 shares

Expires 2033-07-12

F1 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting subject to Ms. Fox's continued service with the Company through the applicable vesting date.

SEC source: 0001209191-23-040423 · doc4.xml · derivative · entry 1

MARAGANORE JOHN · CIK 0001180432 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,128

Underlying: Class A Ordinary Shares · 48,128 shares

Expires 2033-06-29

F1 · shares: These options were granted under the Issuer's non-employee director compensation policy.

F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

SEC source: 0001209191-23-040425 · doc4.xml · derivative · entry 1

Sinha Uma · CIK 0001742587 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,128

Underlying: Class A Ordinary Shares · 48,128 shares

Expires 2033-06-29

F1 · shares: These options were granted under the Issuer's non-employee director compensation policy.

F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

SEC source: 0001209191-23-040424 · doc4.xml · derivative · entry 1

Pereira Brian JG · CIK 0001298146 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,128

Underlying: Class A Ordinary Shares · 48,128 shares

Expires 2033-06-29

F1 · shares: These options were granted under the Issuer's non-employee director compensation policy.

F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

SEC source: 0001209191-23-040422 · doc4.xml · derivative · entry 1

Lotvin Alan · CIK 0001472795 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,128

Underlying: Class A Ordinary Shares · 48,128 shares

Expires 2033-06-29

F1 · shares: These options were granted under the Issuer's non-employee director compensation policy.

F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

SEC source: 0001209191-23-040421 · doc4.xml · derivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,128

Underlying: Class A Ordinary Shares · 48,128 shares

Expires 2033-06-29

F1 · shares: These options were granted under the Issuer's non-employee director compensation policy.

F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

SEC source: 0001209191-23-040420 · doc4.xml · derivative · entry 1

Jimenez Santos Jose Ignacio · CIK 0001937007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,128

Underlying: Class A Ordinary Shares · 48,128 shares

Expires 2033-06-29

F1 · shares: These options were granted under the Issuer's non-employee director compensation policy.

F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

SEC source: 0001209191-23-040419 · doc4.xml · derivative · entry 1

DOYLE WILLIAM F · CIK 0001194459 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,128

Underlying: Class A Ordinary Shares · 48,128 shares

Expires 2033-06-29

F1 · shares: These options were granted under the Issuer's non-employee director compensation policy.

F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

SEC source: 0000899140-23-000514 · form4.xml · nonDerivative · entry 2

Cowen Aaron · CIK 0001869640 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 4,050,675

F3 · kind: See Exhibit 99.1

F3 · shares: See Exhibit 99.1

F3 · price: See Exhibit 99.1

F3 · ownership.nature: See Exhibit 99.1

F4 · ownership.nature: See Exhibit 99.1

SEC source: 0000899140-23-000514 · form4.xml · nonDerivative · entry 1

Cowen Aaron · CIK 0001869640 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 3,193,175

F1 · kind: See Exhibit 99.1

F1 · shares: See Exhibit 99.1

F1 · price: See Exhibit 99.1

F2 · balance_after: See Exhibit 99.1

F2 · ownership.nature: See Exhibit 99.1

F4 · ownership.nature: See Exhibit 99.1

SEC source: 0001209191-23-003719 · doc4.xml · derivative · entry 1

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Class A Ordinary Shares · 250,000 shares

Expires 2033-01-16

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on January 16, 2023.

SEC source: 0001209191-23-003717 · doc4.xml · derivative · entry 1

McKenzie Libbie Parker · CIK 0001936222 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Class A Ordinary Shares · 250,000 shares

Expires 2033-01-16

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on January 16, 2023.

SEC source: 0001209191-23-003720 · doc4.xml · derivative · entry 1

Weger Mary · CIK 0001638460 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,000

Underlying: Class A Ordinary Shares · 185,000 shares

Expires 2033-01-16

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on January 16, 2023.

SEC source: 0001209191-23-003714 · doc4.xml · derivative · entry 1

Jain Deepak · CIK 0001936247 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 585,000

Underlying: Class A Ordinary Shares · 585,000 shares

Expires 2033-01-16

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on January 16, 2023.

SEC source: 0001209191-23-003713 · doc4.xml · derivative · entry 1

Girolamo Todd C · CIK 0001891257 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 290,000

Underlying: Class A Ordinary Shares · 290,000 shares

Expires 2033-01-16

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on January 16, 2023.

SEC source: 0001209191-23-003711 · doc4.xml · derivative · entry 1

Coulston James · CIK 0001936203 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 290,000

Underlying: Class A Ordinary Shares · 290,000 shares

Expires 2033-01-16

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on January 16, 2023.

SEC source: 0001209191-23-003705 · doc4.xml · derivative · entry 1

Bertram Timothy · CIK 0001488033 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,011,500

Underlying: Class A Ordinary Shares · 1,011,500 shares

Expires 2033-01-16

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on January 16, 2023.

SEC source: 0001209191-23-002376 · doc4.xml · derivative · entry 1

Weger Mary · CIK 0001638460 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 450,000

Underlying: Class A Ordinary Shares · 450,000 shares

Expires 2032-12-01

F1 · derivative.exercise_date: The right to purchase common stock vests over four years as follows: 25% on December 1, 2023 and the remaining 75% in substantially equal monthly installments over a 36 month period beginning on December 1, 2023.

SEC source: 0001209191-22-054435 · doc4.xml · derivative · entry 1

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 418,076

Underlying: Class A Ordinary Shares · 418,076 shares

Expires 2032-10-20

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on October 19, 2022.

SEC source: 0001209191-22-054432 · doc4.xml · derivative · entry 1

McKenzie Libbie Parker · CIK 0001936222 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 696,793

Underlying: Class A Ordinary Shares · 696,793 shares

Expires 2032-10-20

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on October 19, 2022.

SEC source: 0001209191-22-054431 · doc4.xml · derivative · entry 1

Jain Deepak · CIK 0001936247 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 929,507

Underlying: Class A Ordinary Shares · 929,507 shares

Expires 2032-10-20

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on October 19, 2022.

SEC source: 0001209191-22-054429 · doc4.xml · derivative · entry 1

Girolamo Todd C · CIK 0001891257 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 696,793

Underlying: Class A Ordinary Shares · 696,793 shares

Expires 2032-10-20

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on October 19, 2022.

SEC source: 0001209191-22-054427 · doc4.xml · derivative · entry 1

Coulston James · CIK 0001936203 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 325,170

Underlying: Class A Ordinary Shares · 325,170 shares

Expires 2032-10-20

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on October 19, 2022.

SEC source: 0001209191-22-054426 · doc4.xml · derivative · entry 1

Bertram Timothy · CIK 0001488033 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,639,607

Underlying: Class A Ordinary Shares · 3,639,607 shares

Expires 2032-10-20

F1 · derivative.exercise_date: Awards vest and become exercisable based on the satisfaction of both time and performance vesting conditions. The performance vesting conditions become satisfied in equal one-third tranches upon the Company's Class A ordinary shares exceeding a volume weighted average price hurdle of $15.00, $20.00 and $25.00, respectively, for 20 trading days within any 30 consecutive trading day period occurring prior to July 11, 2027. Once the performance vesting condition for a tranche is satisfied, such tranche will continue to be subject to time-vesting conditions and will vest ratably on each of the first, second and third anniversaries of the date that such tranche satisfied the performance vesting condition described above.

SEC source: 0001209191-22-051021 · doc4.xml · derivative · entry 1

Fox Jennifer A. · CIK 0001841557 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,370

Underlying: Class A ordinary share · 129,370 shares

Expires 2032-09-20

F1 · derivative.exercise_date: The shares underlying the option award vest in three equal annual installments beginning on July 11, 2023, subject to Ms. Fox's continued service as a director of the Company.

SEC source: 0001567619-22-017178 · doc1.xml · nonDerivative · entry 1

Cowen Aaron · CIK 0001869640 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 6,280,175

F1 · shares: Notes are included on Exhibit 99.1.

F2 · balance_after: Notes are included on Exhibit 99.1.

F3 · ownership.nature: Notes are included on Exhibit 99.1.

SEC source: 0001567619-22-016896 · doc1.xml · nonDerivative · entry 3

Cowen Aaron · CIK 0001869640 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 6,273,168

F1 · shares: See Exhibit 99.1

F4 · balance_after: See Exhibit 99.1

F5 · ownership.nature: See Exhibit 99.1

SEC source: 0001567619-22-016896 · doc1.xml · nonDerivative · entry 2

Cowen Aaron · CIK 0001869640 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 6,271,068

F1 · shares: See Exhibit 99.1

F3 · balance_after: See Exhibit 99.1

F5 · ownership.nature: See Exhibit 99.1

SEC source: 0001567619-22-016896 · doc1.xml · nonDerivative · entry 1

Cowen Aaron · CIK 0001869640 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 6,270,006

F1 · shares: See Exhibit 99.1

F2 · balance_after: See Exhibit 99.1

F5 · ownership.nature: See Exhibit 99.1

SEC source: 0000950103-22-012371 · dp177037_4-maraganore.xml · derivative · entry 2

MARAGANORE JOHN · CIK 0001180432 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 614,013

Underlying: Class A Ordinary Shares · 614,013 shares

Expires not disclosed

F3 · security: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis.

F3 · derivative.exercise_price: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis.

F4 · derivative.exercise_price: These 450,156 Common Units and 163,857 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through June 1, 2025. The Common Units and the PMEL RCUs do not expire.

F4 · derivative.exercise_date: These 450,156 Common Units and 163,857 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through June 1, 2025. The Common Units and the PMEL RCUs do not expire.

F4 · derivative.expiration_date: These 450,156 Common Units and 163,857 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through June 1, 2025. The Common Units and the PMEL RCUs do not expire.

SEC source: 0000950103-22-012371 · dp177037_4-maraganore.xml · derivative · entry 1

MARAGANORE JOHN · CIK 0001180432 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 614,013

Underlying: Class A Ordinary Shares · 614,013 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Class B Ordinary Share has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP ("ProKidney") (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis.

F2 · derivative.exercise_price: These 450,156 Class B Ordinary Shares and 163,857 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through June 1, 2025, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire.

F2 · derivative.exercise_date: These 450,156 Class B Ordinary Shares and 163,857 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through June 1, 2025, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire.

F2 · derivative.expiration_date: These 450,156 Class B Ordinary Shares and 163,857 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through June 1, 2025, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire.

SEC source: 0000950103-22-012378 · dp177014_4-weber.xml · derivative · entry 2

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 676,356

Underlying: Class A Ordinary Shares · 676,356 shares

Expires not disclosed

F3 · security: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis.

F3 · derivative.exercise_price: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis.

F4 · derivative.exercise_price: These 199,770 Common Units and 476,586 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire.

F4 · derivative.exercise_date: These 199,770 Common Units and 476,586 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire.

F4 · derivative.expiration_date: These 199,770 Common Units and 476,586 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire.

SEC source: 0000950103-22-012378 · dp177014_4-weber.xml · derivative · entry 1

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 676,356

Underlying: Class A Ordinary Shares · 676,356 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Class B Ordinary Share has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP ("ProKidney") (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis.

F2 · derivative.exercise_price: These 199,770 Class B Ordinary Shares and 476,586 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire.

F2 · derivative.exercise_date: These 199,770 Class B Ordinary Shares and 476,586 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire.

F2 · derivative.expiration_date: These 199,770 Class B Ordinary Shares and 476,586 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire.

SEC source: 0000950103-22-012372 · dp177035_4-legorreta.xml · derivative · entry 3

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 10,500,000

Underlying: Class A Ordinary Shares · 10,500,000 shares

Expires not disclosed

F7 · derivative.exercise_price: The Earnout Rights were received pursuant to the terms of the Business Combination Agreement. Pursuant to the earnout provisions of the Business Combination Agreement, the reporting persons are entitled to receive earnout restricted Common Units ("Earnout RCUs") and earnout restricted Class B Ordinary Shares ("Earnout RSRs" and together with the Earnout RCS, the "Earnout Rights") that vest in three equal tranches based on the achievement of share price milestones set forth below in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnotes (3) and (5) above, may be exchanged for Class A Ordinary Shares at the election of the reporting persons.

F7 · shares: The Earnout Rights were received pursuant to the terms of the Business Combination Agreement. Pursuant to the earnout provisions of the Business Combination Agreement, the reporting persons are entitled to receive earnout restricted Common Units ("Earnout RCUs") and earnout restricted Class B Ordinary Shares ("Earnout RSRs" and together with the Earnout RCS, the "Earnout Rights") that vest in three equal tranches based on the achievement of share price milestones set forth below in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnotes (3) and (5) above, may be exchanged for Class A Ordinary Shares at the election of the reporting persons.

F8 · shares: One-third of the Earnout Rights will vest upon the volume weighted average price ("VWAP") of a Class A Ordinary Share reaching $15.00 per share for any 20 trading days over any consecutive 30 day trading period, an additional one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $20.00 per share for any 20 trading days over any consecutive 30 day trading period and the final one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $25.00 per share for any 20 trading days over any consecutive 30 day trading period, in each case, such share price milestone must be achieved by the fifth anniversary of the Closing.

F7 · derivative.exercise_date: The Earnout Rights were received pursuant to the terms of the Business Combination Agreement. Pursuant to the earnout provisions of the Business Combination Agreement, the reporting persons are entitled to receive earnout restricted Common Units ("Earnout RCUs") and earnout restricted Class B Ordinary Shares ("Earnout RSRs" and together with the Earnout RCS, the "Earnout Rights") that vest in three equal tranches based on the achievement of share price milestones set forth below in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnotes (3) and (5) above, may be exchanged for Class A Ordinary Shares at the election of the reporting persons.

F7 · derivative.expiration_date: The Earnout Rights were received pursuant to the terms of the Business Combination Agreement. Pursuant to the earnout provisions of the Business Combination Agreement, the reporting persons are entitled to receive earnout restricted Common Units ("Earnout RCUs") and earnout restricted Class B Ordinary Shares ("Earnout RSRs" and together with the Earnout RCS, the "Earnout Rights") that vest in three equal tranches based on the achievement of share price milestones set forth below in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnotes (3) and (5) above, may be exchanged for Class A Ordinary Shares at the election of the reporting persons.

F7 · derivative.underlying_shares: The Earnout Rights were received pursuant to the terms of the Business Combination Agreement. Pursuant to the earnout provisions of the Business Combination Agreement, the reporting persons are entitled to receive earnout restricted Common Units ("Earnout RCUs") and earnout restricted Class B Ordinary Shares ("Earnout RSRs" and together with the Earnout RCS, the "Earnout Rights") that vest in three equal tranches based on the achievement of share price milestones set forth below in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnotes (3) and (5) above, may be exchanged for Class A Ordinary Shares at the election of the reporting persons.

F8 · derivative.underlying_shares: One-third of the Earnout Rights will vest upon the volume weighted average price ("VWAP") of a Class A Ordinary Share reaching $15.00 per share for any 20 trading days over any consecutive 30 day trading period, an additional one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $20.00 per share for any 20 trading days over any consecutive 30 day trading period and the final one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $25.00 per share for any 20 trading days over any consecutive 30 day trading period, in each case, such share price milestone must be achieved by the fifth anniversary of the Closing.

F2 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legoretta. Mr. Legoretta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0000950103-22-012372 · dp177035_4-legorreta.xml · derivative · entry 2

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 94,677,968

Underlying: Class A Ordinary Shares · 94,677,968 shares

Expires not disclosed

F5 · derivative.exercise_price: Each Common Unit may, at the election of the reporting persons and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis.

F6 · derivative.exercise_price: 91,677,968 of the Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Common Units were acquired at the Closing pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment for a per unit price of $10. The Common Units do not expire.

F6 · shares: 91,677,968 of the Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Common Units were acquired at the Closing pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment for a per unit price of $10. The Common Units do not expire.

F6 · derivative.exercise_date: 91,677,968 of the Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Common Units were acquired at the Closing pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment for a per unit price of $10. The Common Units do not expire.

F6 · derivative.expiration_date: 91,677,968 of the Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Common Units were acquired at the Closing pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment for a per unit price of $10. The Common Units do not expire.

F6 · derivative.underlying_shares: 91,677,968 of the Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Common Units were acquired at the Closing pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment for a per unit price of $10. The Common Units do not expire.

F6 · balance_after: 91,677,968 of the Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Common Units were acquired at the Closing pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment for a per unit price of $10. The Common Units do not expire.

F2 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legoretta. Mr. Legoretta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0000950103-22-012372 · dp177035_4-legorreta.xml · derivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 94,677,968

Underlying: Class A Ordinary Shares · 94,677,968 shares

Expires not disclosed

F1 · derivative.exercise_price: Does not include any Class B Ordinary Shares held by Control Empresarial de Capitales, S.A. de C.V. ("CEC") which executed a voting agreement pursuant to which through July 11, 2025, CEC will vote all Ordinary Shares beneficially held by it in a manner proportionate to the manner in which all other Class B Ordinary Shares not held by CEC (including those held by Tolerantia) are voted, solely with respect to the election, appointment or removal of any director to the issuer's board of directors.

F3 · derivative.exercise_price: Each Class B Ordinary Share has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on June 10, 2022 (the "Merger Proxy")), be exchanged, together with the paired Common Unit in ProKidney LP ("ProKidney") (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis.

F4 · shares: 91,677,968 of the Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Class B Ordinary Shares were acquired at the closing of the transactions (the "Closing") contemplated by the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement"), pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment (as defined in the Merger Proxy) for a per share price of $10. The Class B Ordinary Shares do not expire.

F4 · derivative.exercise_date: 91,677,968 of the Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Class B Ordinary Shares were acquired at the closing of the transactions (the "Closing") contemplated by the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement"), pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment (as defined in the Merger Proxy) for a per share price of $10. The Class B Ordinary Shares do not expire.

F4 · derivative.expiration_date: 91,677,968 of the Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Class B Ordinary Shares were acquired at the closing of the transactions (the "Closing") contemplated by the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement"), pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment (as defined in the Merger Proxy) for a per share price of $10. The Class B Ordinary Shares do not expire.

F4 · derivative.underlying_shares: 91,677,968 of the Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Class B Ordinary Shares were acquired at the closing of the transactions (the "Closing") contemplated by the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement"), pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment (as defined in the Merger Proxy) for a per share price of $10. The Class B Ordinary Shares do not expire.

F4 · balance_after: 91,677,968 of the Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Class B Ordinary Shares were acquired at the closing of the transactions (the "Closing") contemplated by the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement"), pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment (as defined in the Merger Proxy) for a per share price of $10. The Class B Ordinary Shares do not expire.

F2 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legoretta. Mr. Legoretta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0001209191-22-042045 · doc4.xml · derivative · entry 3

SCS Sponsor III LLC · CIK 0001850379 · Former Director and 10% Owner

Mehta Kishan · CIK 0001850520 · Former Director and 10% Owner

Cowen Aaron · CIK 0001869640 · Former Director and 10% Owner

ChaChaCha DNA III, LLC · CIK 0001869713 · Former Director and 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A ordinary shares · 6,220,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: The Class B ordinary shares were automatically convertible into Class A ordinary shares at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustments, and had no expiration date.

F4 · derivative.exercise_date: The Class B ordinary shares were automatically convertible into Class A ordinary shares at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustments, and had no expiration date.

F4 · derivative.expiration_date: The Class B ordinary shares were automatically convertible into Class A ordinary shares at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustments, and had no expiration date.

F1 · ownership.direct: The Class B ordinary shares held by the reporting owner, SCS Sponsor III LLC (the "Sponsor"), converted to Class A ordinary shares on a one-for-one basis upon the consummation of the business combination between the issuer and ProKidney LP.

F2 · ownership.direct: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA III, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.

SEC source: 0001209191-22-042045 · doc4.xml · nonDerivative · entry 2

SCS Sponsor III LLC · CIK 0001850379 · Former Director and 10% Owner

Mehta Kishan · CIK 0001850520 · Former Director and 10% Owner

Cowen Aaron · CIK 0001869640 · Former Director and 10% Owner

ChaChaCha DNA III, LLC · CIK 0001869713 · Former Director and 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F3 · ownership.direct: Represents the distribution for no consideration by the Sponsor of 6,860,000 Class A ordinary shares to its members pro rata in accordance with their respective interests.

SEC source: 0001209191-22-042045 · doc4.xml · nonDerivative · entry 1

SCS Sponsor III LLC · CIK 0001850379 · Former Director and 10% Owner

Mehta Kishan · CIK 0001850520 · Former Director and 10% Owner

Cowen Aaron · CIK 0001869640 · Former Director and 10% Owner

ChaChaCha DNA III, LLC · CIK 0001869713 · Former Director and 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,860,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.direct: The Class B ordinary shares held by the reporting owner, SCS Sponsor III LLC (the "Sponsor"), converted to Class A ordinary shares on a one-for-one basis upon the consummation of the business combination between the issuer and ProKidney LP.

F2 · ownership.direct: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA III, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.

SEC source: 0000950103-22-012377 · dp177031_4-bertram.xml · derivative · entry 2

Bertram Timothy · CIK 0001488033 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,944,938

Underlying: Class A Ordinary Shares · 4,944,938 shares

Expires not disclosed

F3 · security: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis.

F3 · derivative.exercise_price: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis.

F4 · derivative.exercise_price: These 2,696,469 Common Units and 2,248,469 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire.

F4 · derivative.exercise_date: These 2,696,469 Common Units and 2,248,469 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire.

F4 · derivative.expiration_date: These 2,696,469 Common Units and 2,248,469 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire.

SEC source: 0000950103-22-012377 · dp177031_4-bertram.xml · derivative · entry 1

Bertram Timothy · CIK 0001488033 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,944,938

Underlying: Class A Ordinary Shares · 4,944,938 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Class B Ordinary Share has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP ("ProKidney") (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis.

F2 · derivative.exercise_price: These 2,696,469 Class B Ordinary Shares and 2,248,469 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire.

F2 · derivative.exercise_date: These 2,696,469 Class B Ordinary Shares and 2,248,469 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire.

F2 · derivative.expiration_date: These 2,696,469 Class B Ordinary Shares and 2,248,469 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire.

SEC source: 0000950103-22-012375 · dp177034_4-jain.xml · derivative · entry 2

Jain Deepak · CIK 0001936247 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,567,939

Underlying: Class A Ordinary Shares · 1,567,939 shares

Expires not disclosed

F3 · security: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis.

F3 · derivative.exercise_price: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis.

F4 · derivative.exercise_price: These 937,836 Common Units and 630,103 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire.

F4 · derivative.exercise_date: These 937,836 Common Units and 630,103 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire.

F4 · derivative.expiration_date: These 937,836 Common Units and 630,103 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire.

SEC source: 0000950103-22-012375 · dp177034_4-jain.xml · derivative · entry 1

Jain Deepak · CIK 0001936247 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,567,939

Underlying: Class A Ordinary Shares · 1,567,939 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Class B Ordinary Share has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP ("ProKidney") (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis.

F2 · derivative.exercise_price: These 937,836 Class B Ordinary Shares and 630,103 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire.

F2 · derivative.exercise_date: These 937,836 Class B Ordinary Shares and 630,103 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire.

F2 · derivative.expiration_date: These 937,836 Class B Ordinary Shares and 630,103 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire.